Postprandial hyperglycemia and cardiovascular disease is the heart2d study the answer?

Diabetes Care

Volumn 32, Issue 3, 2009, Pages 521-522

  Ceriello, Antonio ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLUCOSE; HEMOGLOBIN A1C;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; DIABETIC PATIENT; EDITORIAL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; HYPERGLYCEMIA;

EID: 64749115996     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-2209     Document Type: Editorial

References (17)

1. Raz I, Wilson PWF, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ: Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 32:381-386, 2009
2. Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, Tajima N, Tuomilehto J: Postprandial glucose regulation and diabetic complications. Arch Intern Med 164:2090-2095, 2004
3. Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, Anfossi G, Costa G, Trovati M: Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 91: 813-819, 2006
4. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, the STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486-494, 2003
5. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25: 10-16, 200
6. Ceriello A: postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54:1-7, 2005
7. Monnier L, Lapinski H, Colette C: Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26:881-885, 2003
8. Ceriello A, Colagiuri S, Gerich J, Tuomilehto J, Guideline Development Group: Guideline for management of postmeal glucose. Nutr Metab Cardiovasc Dis 18: S17-S33, 2008
9. Ceriello A, Colagiuri S: International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabet Med 25:1151-1156,2008
10. Mazze RS, Strock E, Wesley D, Borgman S, Morgan B, Bergenstal R, Cuddihy R: Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technol Ther 10:149-159, 2008
11. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559, 2008
12. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Harriet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572, 2008
13. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589, 2008
14. Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care 31:714-719, 2008
15. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and micro-vascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
16. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580-591, 2008
17. Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR, the NAVIGATOR Study Group: Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Am Heart J 156:623-632, 2008